Research Methodologies Followed for This Study:
Secondary Research:
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the apheresis market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research:
In the primary research process, industry experts from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Industry experts from the supply side include CEOs, vice presidents, marketing and sales directors, product managers, business development managers, technology and innovation directors of companies providing apheresis, key opinion leaders, and suppliers and distributors. The industry experts from the demand side include hospitals, blood collection centers, transfusion clinics, and healthcare payers.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950
End Users:
The hospitals and transfusion centers segment is expected to grow at the highest CAGR during the forecast period
On the basis of end user, the apheresis market has been segmented into blood collection centers and blood component providers, hospitals and transfusion centers, and other end users. The hospitals and transfusion centers segment is estimated to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing adoption of therapeutic apheresis in the treatment of various diseases, growing indications of therapeutic apheresis, and rising awareness of apheresis as a therapy.
Geographical Growth:
North America accounted for the largest market share in 2018
North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.
Global Leaders:
Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), and Haemonetics Corporation (US) are the leading players in the apheresis market. The global apheresis market size is projected to reach USD 2.7 billion by 2025 from USD 1.7 billion in 2019, at a CAGR of 8.1% during the forecast period.
The key players of this market focus on increasing their market presence with the adoption of both organic and inorganic growth strategies. These include product launches, agreements, partnerships, collaborations, and acquisitions.
Terumo BCT, Inc. (US) was the leading player in the apheresis market and accounted for the largest share in 2018. The company is known for its diversified product offerings in the field of apheresis. Terumo’s products include the Spectra Optia, COBE Spectra, and Trima Accel, and these are widely adopted by blood centers, blood component providers, hospitals, and transfusion centers for donor & therapeutic apheresis purposes. The company has a significant global footprint owing to its strong sales and distribution network.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=950
Fresenius SE & Co. KGaA (Germany) Fresenius is a global player in the apheresis market, with wide geographic coverage. The company has maintained its leading position in the market through its strong distribution networks across the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. The company offers apheresis systems and related disposables for both donor & therapeutic apheresis through its Fresenius Kabi and Fresenius Medical Care business segments. The company strengthens its business operations by expanding its presence in emerging markets. For instance, in 2016, Fresenius introduced the AmiCORE apheresis device in Malaysia, Thailand, and Vietnam. It has a strong product portfolio, and its CE-approved products have helped it in further enhancing its presence in the apheresis market.
Haemonetics Corporation (US) Haemonetics Corporation is a key competitor in the apheresis market for both the collection of cells and therapeutic apheresis. The company has a strong product profile in automated blood component collection. Haemonetics also has a wide geographic presence across the US, Europe, Japan, and Asia, which enables it to cater to its customers across the globe. Around 62% of the company’s revenue is generated from the US market. Haemonetics also focuses on high-growth emerging countries in order to increase its share in the apheresis market. For instance, in 2015, the company expanded its manufacturing unit in Penang (Malaysia).
